FLUTICASONE AND VILANTEROL FORMULATION AND INHALER
A composition comprising particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof, particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof, and 1,1-difluoroethane.
1 . A composition comprising:
particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof;
particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof; and
1,1-difluoroethane (HFA-152a).
2 . The composition of claim 1 , wherein the fluticasone or a pharmaceutically acceptable salt or solvate thereof is fluticasone furoate.
3 . The composition of claim 1 , wherein the vilanterol or a pharmaceutically acceptable salt or solvate thereof is vilanterol trifenatate.
4 . The composition of claim 1 , wherein the propellant consists essentially of 1,1-difluoroethane (HFA-152a).
5 . The composition of claim 1 contained in a canister, wherein the size of the fluticasone particles in the canister is between about 2 micrometers and 4 micrometers.
6 . The composition of claim 1 contained in a canister, wherein the size of the vilanterol trifenatate particles in the canister is between about 1 micrometer and 2 micrometers.
7 - 9 . (canceled)
10 . A composition comprising
particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof;
particulate vilanterol or a pharmaceutically acceptable salt or solvate thereof; and
1,1-difluoroethane (HFA-152a), wherein fluticasone and vilanterol or the pharmaceutically acceptable salts or solvates thereof are the only active medicaments in the composition.
11 . The composition of claim 10 , wherein the fluticasone or a pharmaceutically acceptable salt or solvate thereof is fluticasone furoate.
12 . (canceled)
13 . The composition of claim 10 , wherein the propellant consists essentially of 1,1-difluoroethane (HFA-152a).
14 . The composition of claim 10 contained in a canister, wherein the size of the fluticasone particles in the canister is between about 2 micrometers and 4 micrometers.
15 . The composition of claim 10 contained in a canister, wherein the size of the vilanterol trifenatate particles in the canister is between about 1 micrometer and 2 micrometers.
16 - 18 . (canceled)
19 . An aerosol canister comprising the composition of claim 1 .
20 . The aerosol canister of claim 19 comprising at least one surface having a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group disposed thereon, wherein the primer composition has a coating composition comprising an at least partially fluorinated compound disposed thereon.
21 . (canceled)
22 . The aerosol canister of claim 20 , wherein the at least one surface is at least a portion of a valve surface.
23 . An inhaler comprising the composition of claim 1 .
24 . An aerosol canister comprising the composition of claim 10 .
25 . The aerosol canister of claim 25 comprising at least one surface having a primer composition comprising a silane having two or more reactive silane groups separated by an organic linker group disposed thereon, wherein the primer composition has a coating composition comprising an at least partially fluorinated compound disposed thereon.
26 . The aerosol canister of claim 25 , wherein the at least partially fluorinated compound is a polyfluoropolyether silane.
27 . An inhaler comprising the composition of claim 10 .
28 . An inhaler comprising the aerosol canister of claim 19 .